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the CC BY-NC-ND license (http://creaAbstract Tumour lysis syndrome (TLS) is a potentially fatal complication of malignancy or its
treatment. This uncommon syndrome comprises laboratory findings of hyperuricaemia, hypo-
calcaemia, hyperkalaemia and hyperphosphataemia. A literature search revealed a total of
eight patients, with testicular cancer, who had TLS. All these patients had metastatic disease.
We present a unique case of a 47-year-old gentleman we saw in clinic, who presented with a
rapidly growing right groin mass and acute breathlessness, and discuss the diagnosis and man-
agement of TLS. TLS is extremely rare in testicular cancer but necessitates the awareness of
urologists. TLS can occur spontaneously in testicular malignancy. Cell lysis in a rapidly prolif-
erating germ cell tumour is a possible mechanism. The prompt identification and institution of
management for TLS is crucial to improve clinical outcomes.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Tumour lysis syndrome (TLS) is an oncological emergency,
which is characterized by the derangement of cellularh.com.sg (M. Chow).
f Shanghai Medical Associa-
.09.005
sian Journal of Urology. Producti
tivecommons.org/licenses/by-nc-metabolism that can lead to acute renal impairment,
metabolic acidosis, cardiac rhythm disturbances, seizures
and death [1]. Massive cell lysis results in the release of
large amounts of uric acid, potassium and phosphate into
the systemic circulation. Hyperkalaemia, if untreated, may
cause muscle weakness or paralysis and more significantly,
cardiac arrhythmias and ultimately death [1]. Hyper-
phosphataemia is often associated with hypocalcaemia due
to the precipitation of phosphate with the calcium in tis-
sues. The resultant secondary hypocalcaemia may result inon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
50 M. Chow et al.neuromuscular symptoms such as tetany, laryngospasm and
cardiac arrhythmias. Both hyperuricaemia and hyper-
phosphataemia potentiate the risk of acute kidney injury by
way of uric acid precipitation and calcium phosphate
deposition in the renal tubules, further aggravating the
electrolyte imbalance [2]. Additionally, the products of cell
lysis trigger the release of cytokines, resulting in a systemic
inflammatory response syndrome and frequently multi-
organ failure [1].
TLS most commonly occurs after the initiation of cyto-
toxic therapy in patients with aggressive lymphoma or
leukaemia. However, it may also occur spontaneously with
other types of tumours that have a high proliferative rate,
tumour burden or sensitivity to cytotoxic agents. In the
setting of testicular cancer, a literature search only
revealed eight incidences of TLS in testicular tumours, of
which seven were metastatic and one had nodal involve-
ment [3,4]. TLS occurred spontaneously in three patients,
all of who had metastatic testicular seminomas [3]. The
presence of metastatic disease would be compatible with
an increased tumour burden which consequentially in-
creases the risk of TLS occurring, either spontaneously or
after the initiation of chemotherapy.
We present the case of a 47-year-old gentleman who was
referred for a right groin swelling.
2. Case report
The patient was referred for progressive right groin swelling
of 1-year duration, which had recently rapidly increased in
size over the past 2 weeks. He reported a history of an
undescended right testis, for which he underwent no pre-
vious surgical intervention. He reported good appetite and
denied any weight loss. Physical examination revealed a
15 cm  10 cm firm right groin lump, not extending into the
scrotum. The right testis was not palpable in his scrotum. A
CT abdomen/pelvis scan done prior to the clinic consulta-
tion revealed a 15 cm  11 cm  16 cm right groin solid
mass, which was partly cystic with septations and calcifi-
cation, suggestive of gonadal malignancy. There was no
lymphadenopathy, metastasis or ascites in the abdomen.
The right testis was not seen within the scrotum (Fig. 1).
During the consultation, he was noted to be dyspnoeic and
tachypnoeic but able to speak in full sentences. Upon
further probing, he reported decreased effort tolerance,
breathlessness and bilateral lower limb swelling for the
past 2 days. He was admitted for an urgent CT pulmonaryFigure 1 (A) (B) CT abdomen/pelvis revealed a 15 cm  11 cm
metastasis present. (C) CT pulmonary angiogram revealed no pulmangiogram (CTPA). The CTPA performed excluded pulmo-
nary embolism and lung metastases.
After admission, he was noted to be more tachypnoeic
and struggling to speak in full sentences on the ward. An
arterial blood gas (ABG) performed on 4 L/min of oxygen
revealed severe metabolic acidosis with a pH of 7.08 and a
lactate >10.9 mmol/L. He was promptly transferred to the
intensive care unit (ICU) and intubated to provide me-
chanical ventilatory support. TLS was provisionally diag-
nosed and subsequently confirmed on laboratory findings.
His blood results revealed hyperuricaemia, hyper-
phosphataemia, hyperkalaemia and an elevated creatinine
and urea. Testicular tumour markers revealed a raised
lactate dehydrogenase (LDH) >3800 U/L, and b subunit of
human chorionic gonadotropin (b-hCG) 37 IU/L, with a
normal a-fetoprotein (AFP) 3 mg/L. Post-intubation, he had
a decreased level of consciousness, with a Glasgow coma
scale score of 3 out of 15 despite receiving no intravenous
sedation.
His electrolyte abnormalities were addressed system-
atically. For the hyperkalaemia, he received intravenous
insulin, calcium gluconate and calcium resonium. For the
hyperuricaemia, oral allopurinol via a nasogastric tube
and intravenous rasburicase were administered. In view of
the refractory hyperkalaemia and worsening metabolic
acidosis despite intravenous sodium bicarbonate and
multiple fluid challenges, a vascular catheter was inserted
in his right internal jugular vein; he was started on
continuous renal replacement therapy (CRRT). His systolic
blood pressure dropped to 40e60 mmHg during CRRT,
from approximately 110 mmHg. It was refractory to
intravenous 5% albumin boluses as well as intravenous
noradrenaline. CRRT was discontinued after 60 min as the
persistently low blood pressure resulted in the formation
blood clots in the vascular catheter. Additional inotropic
support in the form of intravenous adrenaline was started.




This case illustrates a rare presentation of a testicular
malignancy. To our knowledge, this is the first case of a
non-metatstatic testicular malignancy, with no nodal
involvement to present with spontaneous TLS. TLS most 16 cm right groin mass. There was no lymphadenopathy or
onary embolism or lung metastasis.
Tumour lysis syndrome in testicular cancer 51commonly occurs after initiation of cytotoxic therapy. In
the testicular malignancy setting, spontaneous occurrence
of TLS is even rarer. In particular, this patient’s CT scans
showed no regional lymphadenopathy or distant metastasis,
unlike previous reported cases where patients with TLS had
metastatic testicular malignancy. Of the eight reported
cases of TLS resulting from testicular malignancy, there
were four patients who had seminomas [5e8]. All the pa-
tients with seminomas had evidence of metastatic disease,
either nodal or distant organ metastases. The other tu-
mours reported included testicular choriocarcinoma [5],
germ cell tumour and non seminomatous tumour [7], all of
which were metastatic. Spontaneous TLS was reported in
three of the cases, of which all were seminomas with
metastatic disease [6,8]. Interestingly, a retrospective
study done by Kattan et al. [9] failed to show the presence
of TLS in 46 cases of germ cell tumours receiving aggressive
cisplatin based chemotherapy. Despite not having any evi-
dence of metastasis, factors contributing to our patient’s
occurrence of TLS would be the size of his tumour and
recent rapid rate of growth, favouring a highly proliferative
malignancy.
3.2. Diagnosis
We arrived at the provisional diagnosis of TLS after taking
into account his unique presentation of acute breathless-
ness, rapidly growing right groin mass, negative findings
from CTPA and ABG showing severe metabolic acidosis.
Despite the prompt recognition of TLS from the time he was
found to be in severe metabolic acidosis and institution of
relevant management, he deteriorated and died, less than
24 h after his clinic consultation. The circumstances of his
demise necessitated that his case had to be referred to the
coroner’s office. After reviewing the clinical case and evi-
dence, the coroner’s office established that the cause of his
death was “Locally Advanced Testicular Malignancy”. A
post-mortem was not performed. The history of an unde-
scended right testis, radiological findings of a solid, partly
cystic groin mass with septation and calcifications in
conjunction with a raised b-hCG point strongly towards a
testicular germ-cell tumour. In this case, the most probable
diagnosis was a rapidly proliferating testicular germ cell
tumour. Testicular lymphoma remains a distant possibility,
however it is extremely unlikely as there was no evidence
of lymphadenopathy in the chest, abdomen or pelvis. The
intravenous contrast from the CT abdomen, pelvis and
pulmonary angiogram may have further contributed to
renal insult hence aggravating the TLS. Unfortunately, not
all of the published case reports described the process in
which the diagnosis of TLS was made in these patients with
testicular malignancy. A common presentation was pro-
gressive dyspnoea that led on to further investigations
being performed. Most of them had documented evidence
of elevated creatinine, LDH and uric acid.
3.3. Management
The occurrence of TLS is multifactorial; attributes such as
age, LDH levels, white cell count, baseline creatinine, co-
morbidities and cancer type and stage are risk factors [10].The ideal treatment of TLS is prevention. Risk stratification
and initiation of TLS prophylaxis is crucial. Risk stratifica-
tion for TLS based on the above-mentioned risk factors was
developed by Cairo et al. [10] to help indicate which pa-
tients required prophylaxis in the form of close monitoring
with accurate fluid balance charting, intravenous hydration
and medication such as allopurinol or rasburicase. Testic-
ular malignancy, which belongs to the subgroup of solid
tumours are classified as low risk and prophylaxis includes
close monitoring and intravenous hydration with or without
the administration of allopurinol. For patients receiving
cytotoxic agents, those at high risk for developing TLS
should be assessed for clinical signs and biochemical
markers, such as LDH, serum creatinine, uric acid and
electrolytes, every 4e6 h after commencement [11]. The
most important prophylaxis is the hyperhydration with
intravenous fluids. This helps improve renal perfusion and
glomerular filtration and minimizes acidosis (which pro-
motes the precipitation of uric acid crystals) [1]. Fluid
administration also improves urine output which facilitates
the elimination of urates and phosphates [11]. The aim
should be to maintain a urine output of greater than
100 mL/h [12]. Secondly, hypouricaemic agents like allo-
purinol and rasburicase that reduce the level of uric acid
are valuable in the prevention of TLS. However, it is
important to note that while allopurinol prevents the for-
mation of new uric acid by inhibiting xanthine oxidase,
existing uric acid still has to be excreted. Rasburicase is a
recombinant urate oxidase enzyme that metabolises uric
acid to allantoin, hence reducing high levels of uric acid in
addition to preventing hyperuricaemia [1]. Rasburicase is
indicated for patients at higher risk of developing TLS.
Despite appropriate prophylacticmeasures, about 3%e5%
of patients receiving cytotoxic chemotherapy will develop
TLS [13]. In addition to accurate fluid balance charting, pa-
tients should also receive continuous cardiac monitoring
together with 4e6 hourly biochemical testing of creatinine,
uric acid and electrolytes. Hyperkalaemia is the most
dangerous element of TLS as it may cause sudden death
secondary to a cardiac arrhythmia. Hyperkalaemia may be
corrected with intravenous hydration, sodium polystyrene,
sabutamol and intravenous insulin and dextrose. Haemo-
dialysis or hemofiltration to remove the excess potassium is
the last resort. Hypocalcaemia may also result in life-
threatening dysarrhythmias and neuromuscular irritability.
Ensuring that serumphosphate levels are correctedmay help
avoid hypocalcaemia. If required, symptomatic hypo-
calcaemia may be treated calcium supplementation at the
lowest dose possible to relieve symptoms. Regardless of
optimal treatment, severe acute kidney injury may still
occur in some patients. Worsening acidosis, severe acute
kidney injury and refractory electrolyte abnormalities are
indications for renal replacement therapy [14].
Prompt recognition and timely intervention remain the
most crucial elements in the successful management of
patients with TLS. A case report of a patient with meta-
static testicular choriocarcinoma with seminoma, who
developed TLS after receiving adjuvant chemotherapy
illustrated that aggressive intensive care and prompt
intervention led to the prevention of a fatal outcome sec-
ondary to TLS [15].
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In the case of our patient, it was unfortunate that medical
attention was sought so late in the course of his disease.
Despite arriving at the diagnosis of TLS shortly after hos-
pital admission, the prompt measures we initiated were
unable prevent a fatal outcome. His outcome might have
improved with earlier surgical intervention such as an
orchidectomy, to reduce the tumour burden.
4. Conclusion
In conclusion, TLS is extremely rare in untreated, non-
metastatic testicular cancer but necessitates the aware-
ness of urologists. It is important to note that TLS can occur
spontaneously in malignancy; cell lysis in a rapidly prolif-
erating germ cell tumour is a possible mechanism. The
prompt identification and institution of management for
TLS is crucial to improve clinical outcomes.
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